MX2022006883A - Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario. - Google Patents
Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario.Info
- Publication number
- MX2022006883A MX2022006883A MX2022006883A MX2022006883A MX2022006883A MX 2022006883 A MX2022006883 A MX 2022006883A MX 2022006883 A MX2022006883 A MX 2022006883A MX 2022006883 A MX2022006883 A MX 2022006883A MX 2022006883 A MX2022006883 A MX 2022006883A
- Authority
- MX
- Mexico
- Prior art keywords
- multiple myeloma
- relapsed
- isatuximab
- refractory multiple
- treatment
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 5
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 5
- 229950007752 isatuximab Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 abstract 1
- 229960002438 carfilzomib Drugs 0.000 abstract 1
- 108010021331 carfilzomib Proteins 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- 238000009092 lines of therapy Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Ceramic Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
La presente divulgación se refiere a métodos para tratar el mieloma múltiple (como el mieloma múltiple refractario o el mieloma múltiple recidivante y refractario) en un individuo que recibió de una a tres terapias anteriores (o líneas de terapia anteriores) para el mieloma múltiple. Los métodos comprenden la administración al individuo de un anticuerpo anti-CD30, carfilzomib y dexametasona.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944809P | 2019-12-06 | 2019-12-06 | |
| EP20315186 | 2020-04-17 | ||
| US202063023198P | 2020-05-11 | 2020-05-11 | |
| US202063037353P | 2020-06-10 | 2020-06-10 | |
| US202063094833P | 2020-10-21 | 2020-10-21 | |
| PCT/US2020/063468 WO2021113754A1 (en) | 2019-12-06 | 2020-12-04 | Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006883A true MX2022006883A (es) | 2022-11-08 |
Family
ID=74046182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006883A MX2022006883A (es) | 2019-12-06 | 2020-12-04 | Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210171653A1 (es) |
| EP (1) | EP4069740A1 (es) |
| JP (1) | JP2023505219A (es) |
| KR (1) | KR20220159948A (es) |
| CN (1) | CN115698065A (es) |
| AU (1) | AU2020398655A1 (es) |
| BR (1) | BR112022010907A2 (es) |
| CA (1) | CA3164026A1 (es) |
| CO (1) | CO2022009433A2 (es) |
| IL (1) | IL293615A (es) |
| MX (1) | MX2022006883A (es) |
| TW (1) | TW202133880A (es) |
| WO (1) | WO2021113754A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CN112043826A (zh) * | 2013-03-13 | 2020-12-08 | 赛诺菲 | 包含抗cd38抗体和卡非佐米的组合物 |
| JP2016536314A (ja) * | 2013-10-31 | 2016-11-24 | サノフイ | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 |
| KR20200079293A (ko) * | 2017-10-31 | 2020-07-02 | 얀센 바이오테크 인코포레이티드 | 고위험 다발성 골수종을 치료하는 방법 |
-
2020
- 2020-12-04 EP EP20829459.5A patent/EP4069740A1/en active Pending
- 2020-12-04 AU AU2020398655A patent/AU2020398655A1/en active Pending
- 2020-12-04 KR KR1020227023019A patent/KR20220159948A/ko unknown
- 2020-12-04 WO PCT/US2020/063468 patent/WO2021113754A1/en active Application Filing
- 2020-12-04 CA CA3164026A patent/CA3164026A1/en active Pending
- 2020-12-04 MX MX2022006883A patent/MX2022006883A/es unknown
- 2020-12-04 BR BR112022010907A patent/BR112022010907A2/pt unknown
- 2020-12-04 TW TW109142973A patent/TW202133880A/zh unknown
- 2020-12-04 JP JP2022533416A patent/JP2023505219A/ja active Pending
- 2020-12-04 US US17/112,862 patent/US20210171653A1/en active Pending
- 2020-12-04 CN CN202080095185.2A patent/CN115698065A/zh active Pending
- 2020-12-04 IL IL293615A patent/IL293615A/en unknown
-
2022
- 2022-07-05 CO CONC2022/0009433A patent/CO2022009433A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL293615A (en) | 2022-08-01 |
| CO2022009433A2 (es) | 2022-07-29 |
| CN115698065A (zh) | 2023-02-03 |
| AU2020398655A1 (en) | 2022-07-28 |
| BR112022010907A2 (pt) | 2022-10-18 |
| JP2023505219A (ja) | 2023-02-08 |
| WO2021113754A1 (en) | 2021-06-10 |
| TW202133880A (zh) | 2021-09-16 |
| EP4069740A1 (en) | 2022-10-12 |
| KR20220159948A (ko) | 2022-12-05 |
| CA3164026A1 (en) | 2021-06-10 |
| US20210171653A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| WO2019099639A8 (en) | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2021009079A (es) | Metodos para tratar el mieloma multiple. | |
| MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| PH12021551451A1 (en) | Combination hbv therapy | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| TW201613975A (en) | Methods for treating multiple myeloma | |
| WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
| MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
| PH12021552135A1 (en) | Methods of treating al amyloidosis | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2023004314A (es) | Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos. | |
| PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
| SA522431538B1 (ar) | طُرق وتركيبات لعلاج تساقط الشعر | |
| MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
| MX2021002982A (es) | Composiciones y metodos para tratar retinitis pigmentosa. |